Endometriosis: A Clinical Endocannabinoid Deficiency Condition? - Genester Wilson-King, MD

Tags: Etiology, ECS, Endocannabinoid System, Clinical Endocannabinoid Deficiency, Women's Health, Menstruation, THC, CBD

Genester Wilson-King, MD, presents "Endometriosis: A Clinical Endocannabinoid Deficiency Condition?" at CannMed 24.

Endometriosis is a disease that affects women and those assigned female at birth. It can occur in adolescents, postmenopausal people and all ethnicities, races, or color. It’s prevalence is 10 to 15%; it is probably toward the 15% or higher if one includes the aforementioned populations. Endometriosis peaks in prevalence at ages 25 to 35, although with increasing awareness of the disease, these patients are presenting at earlier ages, as early as adolescence. However, people still have a diagnosis delay of 4-11 years. It is a disease that can impact the entire support system.

This talk will describe endometriosis and its clinical signs and symptoms. The etiology is unclear at this time and our current conventional treatment modalities are mediocre at best. It has been postulated to fit the theory of clinical endocannabinoid deficiency condition (CED). What is a CED? Is endometriosis a CED condition? What does the literature say or suggest? Is cannabis uniquely suited to treat the many aspects of it? Let’s take a walk through the literature and see!

Learn More about CannMed: https://cannmedevents.com/